BME:ALM

Stock Analysis Report

Executive Summary

Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide.

Snowflake

Fundamentals

Moderate growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Almirall's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

BME:ALM

1.1%

ES Pharmaceuticals

-1.0%

ES Market


1 Year Return

-4.6%

BME:ALM

8.3%

ES Pharmaceuticals

-3.9%

ES Market

ALM underperformed the Pharmaceuticals industry which returned 8.3% over the past year.

ALM matched the Spain Market (-3.9%) over the past year.


Share holder returns

ALMIndustryMarket
7 Day0%1.1%-1.0%
30 Day-4.4%0.3%3.1%
90 Day3.2%0.9%-2.5%
1 Year-3.6%-4.6%14.3%8.3%-0.7%-3.9%
3 Year21.1%17.1%22.9%9.2%15.4%4.8%
5 Year50.3%42.5%25.2%4.6%1.3%-17.8%

Price Volatility Vs. Market

How volatile is Almirall's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Almirall undervalued based on future cash flows and its price relative to the stock market?

31.53x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Almirall's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Almirall's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Almirall is overvalued based on earnings compared to the Europe Pharmaceuticals industry average.

Almirall is overvalued based on earnings compared to the Spain market.


Price Based on Expected Growth

Almirall is poor value based on expected growth next year.


Price Based on Value of Assets

Almirall is good value based on assets compared to the Europe Pharmaceuticals industry average.


Next Steps

Future Growth

How is Almirall expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

18.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Almirall's revenue is expected to grow by 7.9% yearly, however this is not considered high growth (20% yearly).

Almirall's earnings are expected to grow by 18.1% yearly, however this is not considered high growth (20% yearly).

Almirall's revenue growth is expected to exceed the Spain market average.

Almirall's earnings growth is expected to exceed the Spain market average.

Almirall's earnings growth is expected to exceed the low risk savings rate of 1.5%.


Earnings per Share Growth Estimates


Future Return on Equity

Almirall is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Almirall performed over the past 5 years?

-43.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Almirall's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.

Almirall has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Almirall has become profitable in the last year making it difficult to compare the Europe Pharmaceuticals industry average.


Return on Equity

Almirall has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Almirall used its assets less efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Almirall has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Almirall's financial position?


Financial Position Analysis

Almirall is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Almirall's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Almirall's level of debt (44.6%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (37.7% vs 44.6% today).

Debt is well covered by operating cash flow (33%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 30.5x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1x debt.


Next Steps

Dividend

What is Almirall's current dividend yield, its reliability and sustainability?

1.58%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Almirall's pays a lower dividend yield than the bottom 25% of dividend payers in Spain (2.03%).

Almirall's dividend is below the markets top 25% of dividend payers in Spain (5.35%).

Almirall is not paying a notable dividend for Spain, therefore no need to check if the payments are stable.

Almirall is not paying a notable dividend for Spain, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Almirall's dividends as it is not paying a notable one for Spain.


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (4.1x coverage).


Next Steps

Management

What is the CEO of Almirall's salary, the management and board of directors tenure and is there insider trading?

8.6yrs

Average board tenure


CEO

Peter Guenter (57yo)

2.1yrs

Tenure

0

Mr. Peter Guenter has been Chairman of Management Board and Chief Executive Officer at Almirall, S.A. since August 28, 2017 and it Executive Director since October 10, 2017. Mr. Guenter served as an Execut ...


Board Age and Tenure

8.6yrs

Average Tenure

70yo

Average Age

The tenure for the Almirall board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jorge Gallardo Ballart (63yo)

    Chairman & President

    • Tenure: 0yrs
    • Compensation: €455.00k
  • Bhushan Hardas

    Chief Scientific Officer

    • Tenure: 0yrs
  • Joan Figueras Carreras

    General Counsel

    • Tenure: 0yrs
  • Peter Guenter (57yo)

    CEO, Chairman of Management Board & Executive Director

    • Tenure: 2.1yrs
  • Eloi Crespo Cervera

    VP of Manufacturing & Technical Services and Member of Management Board

    • Tenure: 0yrs
  • Alfredo Barón de Juan

    Executive VP of Global Commercial Operations & Member of Management Board

    • Tenure: 0yrs
  • David Nieto

    CFO, Executive VP of Finance & Member of Management Board

    • Tenure: 0yrs
  • Jordi Sabé Richer

    Senior VP of Corporate Development & Member of Management Board

    • Tenure: 0yrs
  • Amita Kent

    Senior VP of Legal

    • Tenure: 0yrs
  • Esteve Conesa

    VP of Human Resources & Member of Management Board

    • Tenure: 0yrs

Board Members

  • Sidney Taurel (70yo)

    Member of Global Advisory Board-Spain

    • Tenure: 10.7yrs
  • Gerhard Mayr (73yo)

    External Independent Director

    • Tenure: 6.9yrs
    • Compensation: €122.00k
  • Tom McKillop (76yo)

    External Independent Director

    • Tenure: 10.3yrs
    • Compensation: €132.00k
  • Juan Arena de la Mora (76yo)

    External Independent Director

    • Tenure: 12.3yrs
    • Compensation: €124.00k
  • Jorge Gallardo Ballart (63yo)

    Chairman & President

    • Tenure: 0yrs
    • Compensation: €455.00k
  • Karin Louise Dorrepaal (58yo)

    External Independent Director

    • Tenure: 6.7yrs
    • Compensation: €122.00k
  • Daniel Bravo Andreu

    Vice-Chairman

    • Tenure: 0yrs
    • Compensation: €50.00k
  • José Juan Pintó Sala

    Secretary & Non-Voting Director

    • Tenure: 0yrs
  • Joan Figueras Carreras

    General Counsel

    • Tenure: 0yrs
  • Peter Guenter (57yo)

    CEO, Chairman of Management Board & Executive Director

    • Tenure: 2.1yrs

Company Information

Almirall, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Almirall, S.A.
  • Ticker: ALM
  • Exchange: BME
  • Founded: 1943
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €2.781b
  • Shares outstanding: 174.55m
  • Website: https://www.almirall.com

Number of Employees


Location

  • Almirall, S.A.
  • Ronda General Mitre, 151
  • Barcelona
  • Catalonia
  • 8022
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALMBME (Bolsas y Mercados Espanoles)YesCommon StockESEURJun 2007
E2ZDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2007
0O9BLSE (London Stock Exchange)YesCommon StockGBEURJun 2007
LBTS.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2007
ALMEBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURJun 2007

Biography

Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide. The company offers its products for dermatological diseases comprising actinic  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 20:56
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.